Immunosuppressants drugs - for COVID-19 mild to moderate method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deathsno RCT reported results for this endpoint, but 1 observational studies are available. Clear RCT filter to include observational studies
deaths (time to event analysis only)no RCT reported results for this endpoint, but 1 observational studies are available. Clear RCT filter to include observational studies
clinical improvement 1.15 [0.90, 1.47]> 10%1 study (1 / -)86.8 %lownot evaluable highimportant-
clinical improvement (time to event analysis only) 1.15 [0.90, 1.47]> 10%1 study (1 / -)86.8 %lownot evaluable highimportant-
clinical worsening 0.55 [0.33, 0.92]< 10%1 study (1 / -)98.9 %lownot evaluable highimportant-
death or ventilation 0.56 [0.32, 0.97]< 10%1 study (1 / -)98.0 %lownot evaluable highimportant-
hospital discharge 0.25 [0.22, 0.28]> 10%1 study (1 / -)0.0 %lownot evaluable highimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 90 90